Abstract:
BACKGROUND:Canadian patients, healthcare providers and payers share interest in assessing the value of self-monitoring of blood glucose (SMBG) for individuals with type 2 diabetes but not on insulin. Using the UKPDS (UK Prospective Diabetes Study) model, the Canadian Optimal Prescribing and Utilization Service (COMPUS) conducted an SMBG cost-effectiveness analysis. Based on the results, COMPUS does not recommend routine strip use for most adults with type 2 diabetes who are not on insulin. Cost-effectiveness studies require many assumptions regarding cohort, clinical effect, complication costs, etc. The COMPUS evaluation included several conservative assumptions that negatively impacted SMBG cost effectiveness. OBJECTIVES:Current objectives were to (i) review key, impactful COMPUS assumptions; (ii) illustrate how alternative inputs can lead to more favourable results for SMBG cost effectiveness; and (iii) provide recommendations for assessing its long-term value. METHODS:A summary of COMPUS methods and results was followed by a review of assumptions (for trial-based glycosylated haemoglobin [HbA(1c)] effect, patient characteristics, costs, simulation pathway) and their potential impact. The UKPDS model was used for a 40-year cost-effectiveness analysis of SMBG (1.29 strips per day) versus no SMBG in the Canadian payer setting. COMPUS assumptions for patient characteristics (e.g. HbA(1c) 8.4%), SMBG HbA(1c) advantage (-0.25%) and costs were retained. As with the COMPUS analysis, UKPDS HbA(1c) decay curves were incorporated into SMBG and no-SMBG pathways. An important difference was that SMBG HbA(1c) benefits in the current study could extend beyond the initial simulation period. Sensitivity analyses examined SMBG HbA(1c) advantage, adherence, complication history and cost inputs. Outcomes (discounted at 5%) included QALYs, complication rates, total costs (year 2008 values) and incremental cost-effectiveness ratios (ICERs). RESULTS:The base-case ICER was $Can63 664 per QALY gained; approximately 56% of the COMPUS base-case ICER. SMBG was associated with modest risk reductions (0.10-0.70%) for six of seven complications. Assuming an SMBG advantage of -0.30% decreased the current base-case ICER by over $Can10 000 per QALY gained. With adherence of 66% and 87%, ICERs were (respectively) $Can39 231 and $Can54 349 per QALY gained. Incorporating a more representative complication history and 15% complication cost increase resulted in an ICER of $Can49 743 per QALY gained. CONCLUSIONS:These results underscore the importance of modelling assumptions regarding the duration of HbA(1c) effect. The current study shares several COMPUS limitations relating to the UKPDS model being designed for newly diagnosed patients, and to randomized controlled trial monitoring rates. Neither study explicitly examined the impact of varying the duration of initial HbA(1c) effects, or of medication or other treatment changes. Because the COMPUS research will potentially influence clinical practice and reimbursement policy in Canada, understanding the impact of assumptions on cost-effectiveness results seems especially important. Demonstrating that COMPUS ICERs were greatly reduced through variations in a small number of inputs may encourage additional clinical research designed to measure SMBG effects within the context of optimal disease management. It may also encourage additional economic evaluations that incorporate lessons learned and best practices for assessing the overall value of SMBG for type 2 diabetes in insulin-naive patients.
journal_name
Appl Health Econ Health Policyjournal_title
Applied health economics and health policyauthors
Tunis SLdoi
10.2165/11594270-000000000-00000subject
Has Abstractpub_date
2011-11-01 00:00:00pages
351-65issue
6eissn
1175-5652issn
1179-1896journal_volume
9pub_type
杂志文章abstract:OBJECTIVES:To describe how post-market utilisation analysis in Australia informs cost-effectiveness assessment and pricing decisions, using aflibercept and ranibizumab as case studies. METHODS:Pharmaceutical claims were used to identify initiators of aflibercept and ranibizumab in the year after aflibercept-listing (D...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-018-0440-4
更新日期:2019-06-01 00:00:00
abstract::This paper examines the use of propensity score matching in economic analyses of observational data. Several excellent papers have previously reviewed practical aspects of propensity score estimation and other aspects of the propensity score literature. The purpose of this paper is to compare the conceptual foundation...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-013-0075-4
更新日期:2014-02-01 00:00:00
abstract:BACKGROUND:Total hip replacement (THR) must be managed in a more sustainable manner. More cost-effective surgical techniques and the centralization/regionalization of services are two solutions. The former requires an assessment of newer minimally invasive and muscle-sparing surgical techniques. The latter necessitates...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-016-0260-3
更新日期:2016-12-01 00:00:00
abstract:BACKGROUND:Price, income and health status are likely to affect the demand for healthcare in developing countries, and their quantitative effects are unclear in the literature. Some studies report that prices are not important determinants, while others conclude that prices are important determinants of the demand for ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/BF03256160
更新日期:2009-01-01 00:00:00
abstract::We conducted a scoping review with the objective of synthesizing available literature and mapping what designs and methods have been used to evaluate health insurance reforms in sub-Saharan Africa. We systematically searched for scientific and grey literature in English and French published between 1980 and 2017 using...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-019-00499-y
更新日期:2020-12-01 00:00:00
abstract:BACKGROUND:Updated treatment guidelines for atrial fibrillation (AF) have been released by the National Institute for Health and Care Excellence (NICE) in the UK, and highlight a current shortfall in the prescription of anticoagulants to patients with AF for stroke prevention. OBJECTIVE:To design a budget impact model...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-015-0180-7
更新日期:2015-10-01 00:00:00
abstract::A routine part of the process for developing National Institute for Health and Care Excellence (NICE) medical technologies guidance is a submission of clinical and economic evidence by the technology manufacturer. The Birmingham and Brunel Consortium External Assessment Centre (EAC; a consortium of the University of B...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-014-0117-6
更新日期:2014-10-01 00:00:00
abstract:BACKGROUND:In virologically suppressed patients, switching to darunavir/ritonavir (DRV/r) monotherapy maintains HIV RNA suppression, and could also lower treatment costs. OBJECTIVE:The purpose of this analysis was to calculate the potential cost savings from the use of DRV/r monotherapy in the UK. METHODS:In the MONE...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,随机对照试验
doi:10.2165/11592220-000000000-00000
更新日期:2011-07-01 00:00:00
abstract:BACKGROUND:The management of the large patient population in Italy receiving long-term oral anticoagulation therapy (OAT) poses organizational challenges that are traditionally approached with a centralized procedure, relying on hospital-based clinics and/or GPs. However, the availability of near-patient testing device...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/11313890-000000000-00000
更新日期:2010-01-01 00:00:00
abstract::This paper critically evaluates the estimates of the cost of Medicare for All (M4A) in the USA. Six studies that estimate the 1-year total cost of M4A in the USA are reviewed. These studies find that M4A would increase national health spending by as much as 16.9% or decrease it by 20.0%, representing a range of estima...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-021-00636-6
更新日期:2021-01-25 00:00:00
abstract:BACKGROUND:Response to growth hormone (GH) therapy may vary between individual patients. Therefore the use of GH in children should be closely monitored to avoid over, under, or ineffective treatment regimens. The treatment response can be evaluated using growth prediction models. In an effort to improve the accuracy o...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-013-0030-4
更新日期:2013-06-01 00:00:00
abstract::There is wide consensus that the ways in which providers are reimbursed by third parties will affect their behaviour and, hence, the efficient use of limited resources and the performance of health systems. However, there seems to be little evidence on how payment to hospital-based doctors affects hospital performance...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:
更新日期:2003-01-01 00:00:00
abstract:BACKGROUND:Hepatocellular carcinoma (HCC) is the second most common cancer in Taiwan. For males in Taiwan, it is the most dangerous cancer, with both the highest incidence and mortality rate. OBJECTIVE:To determine cancer-related medical care costs for long-term survivors of HCC. METHODS:The estimation of the lifetim...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/00148365-200806010-00005
更新日期:2008-01-01 00:00:00
abstract:BACKGROUND:Treatment with antipsychotic medication is an important element of relapse prevention in the management of schizophrenia, and can reduce inpatient stays. Recently, the long-acting atypical antipsychotic paliperidone long-acting injectable (PLAI), a once-monthly LAI antipsychotic, was approved for treatment o...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-013-0050-0
更新日期:2013-10-01 00:00:00
abstract::The biotech industry now accounts for a substantial and growing proportion of total R&D spending on new medicines. However, compared with the pharmaceutical industry, the biotech industry is financially fragile. This article illustrates the financial fragility of the biotech and pharmaceutical industries in the US and...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/BF03256149
更新日期:2009-01-01 00:00:00
abstract::The debate surrounding whether the findings of efficacy studies are applicable to real-world treatment situations is ongoing. The issue of lack of applicability due to a lack of clinical heterogeneity could be addressed by employing less restrictive inclusion criteria. Given that health economic assessments based on c...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/11590150-000000000-00000
更新日期:2011-05-01 00:00:00
abstract:BACKGROUND:Cost-effectiveness analyses (CEAs) have been performed for oral non-disease-altering osteoarthritis (OA) treatments for well over a decade. During that period the methods for performing these analyses have evolved as pharmacoeconomic methods have advanced, new treatments have been introduced, and the knowled...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-013-0061-x
更新日期:2013-12-01 00:00:00
abstract::The South Korean Government recently announced a reform in the drug anti-rebate law, with the purpose of eradicating pervasive, unethical, and illegal rebate practices in pharmaceutical marketing. The main objective of this reform is to have the ability to bring criminal charges against doctors and pharmacists for rec...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-013-0029-x
更新日期:2013-08-01 00:00:00
abstract::The Peristeen transanal irrigation system is intended to allow people with bowel dysfunction to flush out the lower part of the bowel as part of their bowel management strategy. Peristeen was the subject of an evaluation by the National Institute for Health and Care Excellence, through its Medical Technologies Evaluat...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-018-0447-x
更新日期:2019-02-01 00:00:00
abstract::Smoking of tobacco products is a major public health challenge in prison settings in most countries. Although tobacco use was tolerated by custodial authorities for many decades, the overwhelming evidence of the adverse public health effects of tobacco on both the smokers and those in the vicinity of exhaled or passiv...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:
更新日期:2002-01-01 00:00:00
abstract:BACKGROUND:Employers are increasingly relying on rewards programmes in an effort to promote greater levels of activity among employees; however, if enrolment in these programmes is dominated by active employees, then they are unlikely to be a good use of resources. OBJECTIVE:This study uses a stated-preference survey ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-017-0327-9
更新日期:2017-10-01 00:00:00
abstract::In Germany, the Institute for Quality and Efficiency in Health Care (IQWiG) makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effectiveness. To set ceiling prices, IQWiG uses the following decision rule: the incremental cost-effectiveness ratio (ICER) of a n...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/11586640-000000000-00000
更新日期:2011-03-01 00:00:00
abstract:OBJECTIVES:The objective of this study was to construct an early economic evaluation for acalabrutinib for relapsed chronic lymphocytic leukaemia (CLL) to assist early reimbursement decision making. Scenarios were assessed to find the relative impact of critical parameters on incremental costs and quality-adjusted life...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-019-00496-1
更新日期:2019-12-01 00:00:00
abstract:OBJECTIVE:Several EU countries are determining reimbursement prices of pharmaceuticals by cross-referencing prices of foreign countries. Our objective is to quantify the theoretical cross-border spill-over effects of cross-reference pricing schemes on pharmaceutical prices in the former EU-15 countries. METHODS:An ana...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/00148365-200605040-00005
更新日期:2006-01-01 00:00:00
abstract:OBJECTIVES:The aim of this study was to review all published economic evaluations of guideline-based care for chronic wounds and to assess how useful these studies are for decision making in health services. METHODS:Embase, PubMed, Scopus, Health Technology Assessment (HTA) and National Health Service Economic Evaluat...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-018-0403-9
更新日期:2018-10-01 00:00:00
abstract::The aim of the review is to establish whether, on the basis of previous published evidence, current accepted guidance for health economic evaluation needs to be adapted to evaluate healthcare based on use of genetic information. Online literature search strategies were designed (using PubMed and the NHS Economic Evalu...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.2165/00148365-200605010-00004
更新日期:2006-01-01 00:00:00
abstract:BACKGROUND:Although suicide-prevention campaigns have been implemented in numerous countries, Canada has yet to implement a strategy nationally. This is the first study to examine the cost utility of the implementation of a multidimensional suicide-prevention program that combines several interventions over a 50-year t...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-019-00511-5
更新日期:2020-04-01 00:00:00
abstract::Central line-associated bloodstream infections (CLABSIs) are primary, laboratory confirmed bloodstream infections in patients with a central line within 48 h of symptom onset. Catheter-related bloodstream infection (CRBSI) is a more specific term used when the cause of infection has been confirmed by catheter tip cult...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-020-00602-8
更新日期:2020-08-05 00:00:00
abstract:CONTEXT:The in-hospital costs of extracorporeal membrane oxygenation (ECMO) have not been well established. OBJECTIVE:To evaluate the in-hospital costs of ECMO technology in both US and non-US settings for all patient types. DATA SOURCES:Systematic review of English-language articles, using the PubMed, Embase, Web of...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-015-0170-9
更新日期:2015-08-01 00:00:00
abstract::This article aims to define a value-based approach to pricing and reimbursement for off-patent originators using a multiple criteria decision analysis (MCDA) approach centered on a systematic analysis of current pricing and reimbursement policies in China. A drug price policy review was combined with a quantitative an...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-014-0150-5
更新日期:2015-08-01 00:00:00